Superluminal Medicines Secures $60 Million in Series B Funding to Advance Obesity Program and Drug Discovery Platform
PRIVATESep 06, 2026
Amount Raised
$60 Million
Round Type
Series B
BostonBiotechnologyHealth Care
Investors
Deep Track CapitalInsight PartnersPerceptive AdvisorsBVF PartnersNvidiaCatalio Capital ManagementGaingelsCooleyEli LillyRA Capital Management
Description
Superluminal Medicines has successfully raised an oversubscribed $60 million in Series B financing led by BVF Partners. This funding will enable the company to transition from a discovery-stage platform to a clinical-stage biotechnology firm, helping to advance its lead obesity program into clinical development.
Who to call at Superluminal Medicines, and when
A new round usually means Superluminal Medicines is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Superluminal Medicines raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Superluminal Medicines, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Superluminal Medicines
Location
Boston, Massachusetts, United States
About
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Superluminal Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyHealth Care